| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d79362493392629399a529d819cdccd8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2021-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d20c783a5efcef4f95420d1ad30ede63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1105cffc530f6f40b8756660c695393a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3404aa3af99872f47536ac9f85f36460
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40c2f3e17557b1c62f2a72ef0868ca63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_351b501183835f0dfe41a4d3833399e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f0e4b575ef41e1714aa973c3d3e51a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_684f75a5597e54af45c4c4edbc2bcff6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_662c695650f490decd630ae794ce7674 |
| publicationDate |
2022-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022079939-A1 |
| titleOfInvention |
Aripiprazole prodrug composition |
| abstract |
Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition. |
| priorityDate |
2014-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |